| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q3 2012 | ||||||||
About Eventide Asset Management
Eventide Asset Management is a Boston-based investment firm that specializes in providing investment solutions to investors who are looking for long-term growth opportunities. The company was founded in 2008 by a group of experienced investment professionals who shared a common vision of creating a firm that would focus on investing in companies that are making a positive impact on society.
The company's investment philosophy is based on the belief that companies that are making a positive impact on society are more likely to be successful in the long run. Eventide's investment team conducts extensive research to identify companies that are aligned with this philosophy and have the potential to deliver strong returns over the long term.
The company's investment strategies are managed by a team of experienced professionals, including CEO Robin John, COO Finny Kuruvilla, and Chief Investment Officer, Dr. Finny Kuruvilla. The team has a proven track record of delivering strong returns to investors, and their investment strategies have been recognized by industry experts.
Eventide Asset Management offers a range of investment solutions, including mutual funds, separately managed accounts, and exchange-traded funds (ETFs). The company's funds are available to individual investors, financial advisors, and institutional investors.
Overall, Eventide Asset Management is a reputable investment firm that has a strong focus on investing in companies that are making a positive impact on society. The company's experienced investment team and proven track record make it a compelling option for investors who are looking for long-term growth opportunities.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LOWES COS INC | 43 | Q2 2024 | 3.2% |
| PALO ALTO NETWORKS INC | 43 | Q2 2024 | 3.6% |
| ASML HOLDINGS NV | 43 | Q2 2024 | 1.9% |
| REPLIGEN CORP | 43 | Q2 2024 | 0.5% |
| VERACYTE INC | 41 | Q2 2024 | 1.5% |
| NEUROCRINE BIOSCIENCES INC | 40 | Q3 2023 | 1.1% |
| LAM RESEARCH CORP | 38 | Q2 2024 | 3.4% |
| COLLEGIUM PHARMACEUTICAL INC | 37 | Q2 2024 | 2.6% |
| BLUEPRINT MEDICINES CORP | 36 | Q2 2024 | 1.3% |
| XPO LOGISTICS INC | 34 | Q1 2023 | 3.8% |
View Eventide Asset Management's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 908 Devices Inc. | February 14, 2024 | 1,430,995 | 4.4% |
| Annexon, Inc.Sold out | February 14, 2024 | 0 | 0.0% |
| Celldex Therapeutics, Inc. | February 14, 2024 | 3,630,013 | 6.6% |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2024 | 2,630,478 | 8.1% |
| Freeline Therapeutics Holdings plcSold out | February 14, 2024 | 0 | 0.0% |
| Inozyme Pharma, Inc. | February 14, 2024 | 3,179,837 | 5.2% |
| Korro Bio, Inc. | February 14, 2024 | 546,325 | 6.8% |
| MARINUS PHARMACEUTICALS, INC. | February 14, 2024 | 4,529,997 | 8.3% |
| Mirum Pharmaceuticals, Inc. | February 14, 2024 | 2,693,581 | 5.8% |
| Praxis Precision Medicines, Inc.Sold out | February 14, 2024 | 0 | 0.0% |
View Eventide Asset Management's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-27 |
| 13F-HR | 2024-08-13 |
| SC 13G/A | 2024-08-09 |
| 13F-HR | 2024-05-15 |
| 13F-HR/A | 2024-02-20 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Eventide Asset Management's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.